Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Rosetta Genomics and NYU School of Medicine have expanded their collaboration to screen for specific microRNA biomarkers and signatures that may be used to diagnose and target congenital heart disease in newborns.
Subscribe to our email newsletter
According to Rosetta, recent studies have revealed key roles of microRNAs as regulators of growth, development, function and responses to stress in the heart. The company said that it believes these regulatory mechanisms may serve as potential diagnostic biomarkers and therapeutic targets for the treatment of heart disease.
Amir Avniel, CEO and president of Rosetta Genomics, said: “As a cutting-edge research institution, NYU School of Medicine is a close collaborator of Rosetta Genomics in the microRNA field, and I am confident this collaboration will enhance our understanding of the link between microRNAs and various heart conditions.”
David Meyer, director of pediatric and congenital cardiothoracic surgery at NYU School of Medicine, said: “It is now clear that microRNAs play a key role in controlling diverse aspects of cardiac development and response to disease. Rosetta’s extensive knowledge and proprietary technologies in the microRNA field, coupled with our experience in congenital heart disease, is an excellent starting point for this collaboration.”